CANCERS OF PROSTATE AND TESTIS IN THE CZECH AND WORLDWIDE POPULATION

Czech version

Authors: E. Geryk ^*; D. Pacík; A. Čermák; M. Konečný
Authors‘ workplace: Fakultní nemocnice, Brno ^*
Published in: Urol List 2012; 10(1): 19-25

Overview

Of total 899,102 new prostate cancers (PC) in 2008, based in Globocan 2008 (IARC) is estimated 644,044 in more developed and 255,058 in less developed regions, 323,790 in EU, 5,719 in the Czech Republic with expected more than 1,690 thousand cases in the world in 2030. Of total 52,322 new testicular cancers (TC) is estimated 29,228 in more developed and 23,094 in less developed regions, 15,255 in EU, 489 in the Czech Republic with expected nearly 66 thousand cases in the world in 2030. The worldwide numbers aged 65 years and more there were 73.2% of new PC and 87.3% of deaths, respectively 7% and 19% of TC. Czech males reached the 17th order by the crude rate of PC and the 5th order of TC between 20 European countries. In 1959–2008 there were recorded 92,310 PC and 11,693 TC in Czech males, of which were 5,332 (104.3 per 100,000) new PC and 455 (8.9 per 100,000) TC in 2008. Of the worldwide 5-year prevalence 3,200 thousand PC were 42.5% cases and of 201.5 thousand TC were 39.2% cases in Europe. Cross-sectional prevalence in the Czech males increased from 4,935 (98 per 100,000) to 20,436 (408.5 per 100,000) of PC and from 1,944 (38.6 per 100,000) to 6,480 (129.5 per 100,000) of TC. No matter what advances there may be in high-technology medicine, any major reduction in deaths and disability from cancer will come from prevention, not from cure.

Key words:
cancers of prostate and testis, new cases and death, sage distribution, expected numbers in selected regions of the world

Sources

l. Geryk E, Dítě P, Pacík D et al. Zátěž české populace nádory v urologii 1959–2007. Urologie pro praxi 2010; 11(5): 273–277.

2. IARC. Globocan 2008, Lyon: IARC, http://globocan. iarc.fr/

3. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127(12): 2893–2917.

4. Geryk E, Horváth T et al. Zátěž nádory u české populace na pozadí demografie a ekonomiky. ČLČ, 2012; 1, v tisku.

5. ÚZIS. Novotvary 2008 ČR. Zdravotnická statistika. Praha: ÚZIS ČR, 2011; 262, www.uzis,cz

6. http://www.linkos.cz/

7. American Cancer Society. Cancer Facts & Figures

2011. Atlanta: American Cancer Society Inc, NW, Atlanta, GA; 2011: 1–18.

8. Konečný M, Geryk E et al. Prevalence nádorů v České republice, 1989–2005–2015. Brno: PřF MU, 2008.

9. Benson JS, Coogan CL. Urologic malpractice in the United States of America: trends and analysis. Urol list 2011; 9(2): 44–48.

10. Geryk E, Pacík D, Horváth T et al. Budou dosaženy očekávané počty nádorů ledvin a močového měchýře? Urol list 2011; 9(2): 38–43.

11. Abrahamson PA. New developments in the management of prostate cancer“. Abstract book of Conference Individualised prostate cancer care in an advancing world, Nice, 7. 10. 2011: 19.

12. http://www.farmakoekonomika.cz/

13. www.preventio.cz

14. Pacík D. Jaká je skutečnost srovnání konvenčního a roboticky asistovaného přístupu k radikální prostatektomii? Je oprávněné platit vyšší cenu? Přednáška ve Zdravotním výboru parlamentu ČR, 8. 12. 2011 http://www.europauomo.cz/pdf/prednaskaPL.pdf.

15. Mackay J, Jemal A et al. The Cancer Atlas. Am Canc Soc 2006: 82.

16. Kaempe J et al. The cause of death of Tycho Brahe in 1601. Proceedings of the 31st TIAFT Congress, Leipzig 1993, Contributions to Forensic Toxicology. Leipzig: Molina-press 1994: 309–315.

17. Pallon J. Did mercury poisoning cause the death of Tycho Brahe? 1996. www.fixedearth.com/brahe_ poisoned.htm.

18. Gilder J, Gilder Anne-Lee. Heavenly intrique, Johannes Kepler, Tycho Brahe and the murder behind one of history´s greatest scientific discoveries. Doubleday 2004.

Labels

Paediatric urologist Urology

NOCTURIA IN ELDERLY PATIENTS AND ITS CONSEQUENCES; WHICH OPTIONS DO WE HAVE TO INFLUENCE NOCTURIA? WHAT IS POSSIBLE, WHAT IS FEASIBLE AND WHAT IS REASONABLE?

CENTRAL NERVOUS SYSTEM ADVERSE DRUG EVENTS OF ANTIMUSCARINIC MEDICATION

REPORTING AND GRADING OF COMPLICATIONS AFTER UROLOGIC SURGICAL PROCEDURES: AN AD HOC EAU GUIDELINES PANEL ASSESSMENT AND RECOMMENDATIONS

RELATIONSHIPS OF TESTOSTERONE AND PROSTATE CANCER

ACTIVE SURVEILLANCE OF THE SMALL RENAL MASS

RADIOFREQUENCY ABLATION OF RENAL TUMOURS

CURRENT PRINCIPLES AND THERAPEUTIC CONCEPTS OF RETROGRADE INTRA-RENAL SURGERY FOR UROLITHIASIS

ROLE OF ANTIBIOTIC PROPHYLAXIS IN THE MANAGEMENT OF VESICOURETERAL REFLUX

LAPAROSCOPIC PELVIC FLOOR SURGERY. PART I – LAPAROSCOPIC COLPOSUSPENSION. PART II – LAPAROSCOPIC COLPOPEXY

MULTIPLE SCLEROSIS AND LOWER URINARY TRACT DYSFUNCTION. METHODS OF DIAGNOSTICS; TREATMENT AND FOLLOW-UP REQUIREMENTS

Article was published in

Urological Journal

2012 Issue 1